Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Photon counting (PC) detectors allow a reduction of the radiation dose in CT. Chest X-ray (CXR) is known to have a low sensitivity and specificity for detection of pneumonic infiltrates. The aims were to establish an ultra-low-dose CT (ULD-CT) protocol at a PC-CT with the radiation dose comparable to the dose of a CXR and to evaluate its clinical yield in patients with suspicion of pneumonia.

Methods: A ULD-CT protocol was established with the aim to meet the radiation dose of a CXR. In this retrospective study, all adult patients who received a ULD-CT of the chest with suspected pneumonia were included. Radiation exposure of ULD-CT and CXR was calculated. The clinical significance (new diagnosis, change of therapy, additional findings) and limitations were evaluated by a radiologist and a pulmonologist considering previous CXR and clinical data.

Results: Twenty-seven patients (70% male, mean age 68 years) were included. With our ULD-CT protocol, the radiation dose of a CXR could be reached (mean radiation exposure 0.11 mSv). With ULD-CT, the diagnosis changed in 11 patients (41%), there were relevant additional findings in 4 patients (15%), an infiltrate (particularly fungal infiltrate under immunosuppression) could be ruled out with certainty in 10 patients (37%), and the therapy changed in 10 patients (37%). Two patients required an additional CT with contrast medium to rule out a pulmonary embolism or pleural empyema.

Conclusions: With ULD-CT, the radiation dose of a CXR could be reached while the clinical impact is higher with change in diagnosis in 41%.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871675PMC
http://dx.doi.org/10.1159/000536065DOI Listing

Publication Analysis

Top Keywords

radiation dose
24
dose cxr
16
uld-ct protocol
12
photon counting
8
radiation
8
dose chest
8
chest x-ray
8
patients
8
radiation exposure
8
additional findings
8

Similar Publications

The High-Intensity Proton Accelerator Facility at the Paul Scherrer Institute (PSI) accelerates protons to an energy of 590 MeV with currents up to 2.4 mA, i.e.

View Article and Find Full Text PDF

Robot-assisted percutaneous coronary intervention: a prospective, multicenter, randomized controlled, non-inferiority clinical trial.

J Geriatr Cardiol

August 2025

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing,

Objective: To evaluate the safety and effectiveness of robot-assisted percutaneous coronary intervention (R-PCI) compared to traditional manual percutaneous coronary intervention (M-PCI).

Methods: This prospective, multicenter, randomized controlled, non-inferior clinical trial enrolled patients with coronary heart disease who met the inclusion criteria and had indications for elective percutaneous coronary intervention. Participants were randomly assigned to either the R-PCI group or the M-PCI group.

View Article and Find Full Text PDF

Background: To compare doses deposited to the liver during right breast radiotherapy with static and dynamic radiotherapy techniques. The second aim was to introduce the liver load index (LLI), a novel index developed to estimate radiation exposure to the liver prior to treatment selection.

Materials And Methods: We prepared radiotherapy treatment plans for ten patients with right breast cancer.

View Article and Find Full Text PDF

Neuroblastoma is the most common extracranial solid tumor in children, requiring multidisciplinary treatment, including radiotherapy, which is primarily applied in the high-risk group to prevent disease progression. The review highlights indications for radiotherapy, its role in multimodal treatment, and addresses aspects of radiotherapy planning, including target volume definition, prescribed radiation doses, optimal timing for radiotherapy implementation, and potential side effects. Particular attention is drawn to the lack of consensus regarding the necessity of an additional radiation dose for persistent residual disease in the primary tumor and the irradiation of metastatic sites remaining after induction therapy.

View Article and Find Full Text PDF

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer.

Rep Pract Oncol Radiother

August 2025

Department of Oncology and Radiotherapy, University Hospital in Pilsen, Pilsen, Czech Republic.

In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists. OMD is a kind of an "umbrella term" for a variety of clinical situations. This review focuses on the role of radiotherapy (RT) in the treatment of oligometastatic non-small cell lung cancer (OM-NSCLC).

View Article and Find Full Text PDF